Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
Rhythm Pharmaceuticals announced that the FDA has accepted their supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) with Priority Review. The sNDA aims to expand the label to treat obesity due to Bardet-Biedl syndrome (BBS) or POMC/LEPR deficiency in children as young as 2 years old. The FDA set a PDUFA goal date of December 26, 2024.
The sNDA is based on data from a Phase 3 trial in patients aged 2 to 6 years. Results showed a 3.04 mean reduction in BMI-Z score and 18.4% mean reduction in BMI. In July 2024, the European Commission expanded IMCIVREE's marketing authorization for children as young as 2 years old with these conditions.
Rhythm Pharmaceuticals ha annunciato che la FDA ha accettato la loro domanda supplementare per l'applicazione di un nuovo farmaco (sNDA) per IMCIVREE® (setmelanotide) con Revisione Prioritaria. L'sNDA ha l'obiettivo di ampliare l'etichetta per trattare l'obesità dovuta a syndrome di Bardet-Biedl (BBS) o deficienza di POMC/LEPR in bambini di soli 2 anni. La FDA ha fissato una data obiettivo PDUFA del 26 dicembre 2024.
L'sNDA si basa su dati di uno studio di Fase 3 condotto su pazienti di età compresa tra 2 e 6 anni. I risultati hanno mostrato una riduzione media di 3,04 nel punteggio BMI-Z e una riduzione media del 18,4% nel BMI. Nel luglio 2024, la Commissione Europea ha ampliato l'autorizzazione all'immissione in commercio di IMCIVREE per bambini di appena 2 anni con queste condizioni.
Rhythm Pharmaceuticals anunció que la FDA ha aceptado su solicitud suplementaria de nuevo fármaco (sNDA) para IMCIVREE® (setmelanotide) con Revisión Prioritaria. La sNDA tiene como objetivo ampliar la etiqueta para tratar la obesidad debida al sindrome de Bardet-Biedl (BBS) o deficiencia de POMC/LEPR en niños tan pequeños como de 2 años. La FDA estableció una fecha objetivo PDUFA del 26 de diciembre de 2024.
La sNDA se basa en datos de un ensayo de Fase 3 en pacientes de 2 a 6 años. Los resultados mostraron una reducción media de 3.04 en el puntaje BMI-Z y una reducción media del 18.4% en el BMI. En julio de 2024, la Comisión Europea amplió la autorización de comercialización de IMCIVREE para niños tan pequeños como de 2 años con estas condiciones.
리즘 제약(Rhythm Pharmaceuticals)은 FDA가 IMCIVREE® (setmelanotide)에 대한 보완 신약 신청서(sNDA)를 우선 심사 대상으로 수락했다고 발표했습니다. 이 sNDA는 바르데-비들 증후군(BBS) 또는 POMC/LEPR 결핍으로 인한 비만 치료를 위해 2세 어린이에게 사용하기 위한 라벨 확대를 목표로 하고 있습니다. FDA는 2024년 12월 26일을 PDUFA 목표일로 설정했습니다.
이 sNDA는 2세에서 6세 환자를 대상으로 한 3상 시험의 데이터를 기반으로 하고 있습니다. 결과는 BMI-Z 점수에서 평균 3.04 감소와 BMI에서 평균 18.4% 감소를 보여주었습니다. 2024년 7월, 유럽 위원회는 이러한 질환을 가진 2세 어린이를 위해 IMCIVREE의 마케팅 허가를 확대했습니다.
Rhythm Pharmaceuticals a annoncé que la FDA avait accepté sa demande de médicament nouveau complémentaire (sNDA) pour IMCIVREE® (setmelanotide) avec Révision Prioritaire. La sNDA vise à élargir l'étiquette pour traiter l'obésité due au système de Bardet-Biedl (BBS) ou à la déficience de POMC/LEPR chez les enfants dès l'âge de 2 ans. La FDA a fixé une date cible PDUFA au 26 décembre 2024.
La sNDA repose sur des données d'un essai de phase 3 auprès de patients âgés de 2 à 6 ans. Les résultats ont montré une réduction moyenne de 3,04 du score BMI-Z et une réduction moyenne de 18,4% du BMI. En juillet 2024, la Commission européenne a élargi l'autorisation de mise sur le marché d'IMCIVREE pour les enfants dès l'âge de 2 ans atteints de ces affections.
Rhythm Pharmaceuticals gab bekannt, dass die FDA ihren Antrag auf Zulassung eines neuen Medikaments (sNDA) für IMCIVREE® (setmelanotide) mit prioritärer Prüfung angenommen hat. Das sNDA zielt darauf ab, die Kennzeichnung zu erweitern, um Fettleibigkeit aufgrund des Bardet-Biedl-Syndroms (BBS) oder einer POMC/LEPR-Defizienz bei Kindern ab 2 Jahren zu behandeln. Die FDA setzte ein PDUFA-Zieldatum für den 26. Dezember 2024.
Das sNDA basiert auf Daten aus einer Phase-3-Studie bei Patienten im Alter von 2 bis 6 Jahren. Die Ergebnisse zeigten eine durchschnittliche Reduktion des BMI-Z-Scores um 3,04 und eine durchschnittliche Reduktion des BMI um 18,4%. Im Juli 2024 erweiterte die Europäische Kommission die Marktzulassung von IMCIVREE für Kinder ab 2 Jahren mit diesen Bedingungen.
- FDA acceptance of sNDA with Priority Review for IMCIVREE
- Potential label expansion to treat children as young as 2 years old
- Phase 3 trial showed 3.04 mean reduction in BMI-Z score and 18.4% mean reduction in BMI
- European Commission already expanded marketing authorization for children as young as 2 years old
- None.
Insights
The FDA's acceptance of Rhythm Pharmaceuticals' sNDA for IMCIVREE with Priority Review is a significant development for the company. This potential label expansion to include children as young as 2 years old could substantially increase the addressable market for IMCIVREE.
The PDUFA date of December 26, 2024, suggests a relatively quick review process, which is positive for Rhythm. The company's focus on rare genetic obesity disorders positions it in a niche market with competition. If approved, treating younger patients could lead to better long-term outcomes and potentially increased lifetime value per patient.
Investors should note the positive Phase 3 trial results, with a
The potential approval of IMCIVREE for children as young as 2 years old with rare genetic obesity disorders is a significant medical advancement. Early intervention in these conditions is crucial, as hyperphagia and severe obesity can manifest early in life, leading to lifelong health complications.
The 3.04 mean reduction in BMI-Z score observed in the Phase 3 trial is clinically meaningful for this patient population. It suggests that IMCIVREE could effectively manage weight in very young children with these rare genetic conditions, potentially altering the course of their disease.
However, it's important to consider the long-term effects of MC4R agonist use in developing children. While the benefits seem substantial, ongoing monitoring for potential side effects or developmental impacts will be important if the drug is approved for this younger age group.
The potential label expansion for IMCIVREE to include younger children represents a significant market opportunity for Rhythm Pharmaceuticals. Rare disease treatments often command premium pricing and expanding the eligible patient population could boost revenue potential.
The Priority Review status and recent EC approval for the same indication increase the likelihood of FDA approval. This could lead to faster market access and uptake in the U.S. for this expanded indication.
However, investors should consider potential challenges in market access for very young patients. Payers may require additional evidence of long-term benefits and safety in this age group. The orphan drug status of IMCIVREE for these indications could provide some pricing power and market exclusivity, but negotiations with payers for coverage in this younger population will be important for commercial success.
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency --
-- FDA sets PDUFA goal date of December 26, 2024 --
BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency obesity in children as young as 2 years old. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2024.
“This milestone brings us another step closer to offering a precision therapy for young patients in the U.S. experiencing hyperphagia – a pathological hunger that leads to aberrant food-seeking behaviors – and severe obesity caused by rare MC4R pathway diseases,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “IMCIVREE has been approved for more than two years and prescribed to hundreds of patients 6 years old and older, and we believe that treating patients at an even earlier age will positively affect the lives of these children and their families.”
The sNDA submission is based on data from Rhythm’s multi-center, one-year, open-label Phase 3 trial in patients (N=12) between 2 and younger than 6 years old with obesity due to biallelic POMC/PCSK1 or LEPR deficiency or a clinical diagnosis of BBS. The hyperphagia and severe obesity of rare genetically-caused MC4R pathway diseases can present early in life, and these data showed potential efficacy in patients younger than 6 years of age. Treatment with setmelanotide achieved the primary endpoint with a 3.04 mean reduction in BMI-Z score (a measure of body mass index deviations from what is considered normal) and 18.4 percent mean reduction in BMI.
In July 2024, the European Commission (EC) expanded the marketing authorization for IMCIVREE to include children as young as 2 years old with obesity due to BBS or POMC/PCSK1, or LEPR deficiency. In the United States, IMCIVREE is currently indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS), and BBS.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. The EC has also authorized setmelanotide for control of hunger and treatment of obesity in children as young as 2 years old, living with BBS or POMC, PCSK1, or LEPR deficiency. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Setmelanotide Indication
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) or BBS.
In the European Union, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In Europe, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign.
- Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity.
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Skin Pigmentation and Darkening of Pre-Existing Nevi: Generalized increased skin pigmentation and darkening of pre-existing nevi have occurred because of its pharmacologic effect. Full body skin examinations prior to initiation and periodically during treatment should be conducted to monitor pre-existing and new pigmentary lesions.
Heart rate and blood pressure monitoring: In Europe, heart rate and blood pressure should be monitored as part of standard clinical practice at each medical visit (at least every 6 months) for patients treated with setmelanotide.
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Patients who have an erection lasting longer than 4 hours should seek emergency medical attention.
Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Patients should be monitored for new onset or worsening depression or suicidal thoughts or behaviors. Consideration should be given to discontinuing setmelanotide if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue setmelanotide.
Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. In Europe, the prescribing physician should monitor growth (height and weight) using age- and sex-appropriate growth curves.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: Setmelanotide is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥
USE IN SPECIFIC POPULATIONS
Lactation: Not recommended when breastfeeding.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full U.S. Prescribing Information and EU Summary of Product Characteristics for additional Important Safety Information.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress, potential regulatory submissions, approvals and timing thereof of setmelanotide and other product candidates, including the PDUFA goal date of our sNDA discussed herein, the potential benefits of any of the Company’s products or product candidates for any specific disease indication or at any dosage, including the potential benefits of setmelanotide for pediatric patients with BBS or POMC, PCSK1, or LEPR deficiency; expectations surrounding potential regulatory submissions and approvals, including within the United States, the EU and other regions; business strategy and plans, including regarding commercialization of setmelanotide in the United States, the EU and other regions; and the timing of any of the foregoing . Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended June 30, 2024 and other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
FAQ
What is the PDUFA date for Rhythm Pharmaceuticals' IMCIVREE sNDA (RYTM)?
What conditions does the IMCIVREE sNDA aim to treat in younger children (RYTM)?
What were the key results from the Phase 3 trial for IMCIVREE in young children (RYTM)?
Has IMCIVREE received approval for younger children in any other regions (RYTM)?
